Literature DB >> 8940722

9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET.

M M Alauddin1, P S Conti, S M Mazza, F M Hamzeh, J R Lever.   

Abstract

A no-carrier-added synthesis of 9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy)methyl]-guanine ([18F]-FHPG) is reported. The 9-[(1,3-dihydroxy-2-propoxy)methyl)guanine (DHPG) was converted to 9-[N2,O-bis(methoxytrityl)-3-(tosyl)-2-propoxy-methyl]guanine by treatment with methoxytrityl chloride followed by tosylation. The tosylate was reacted with [18F]-KF in the presence of kryptofix 2.2.2. to produce the 3-fluoro-N2-O-bis-(methoxytrityl) derivative. Removal of the methoxytrityl protecting groups by acid hydrolysis produced [18F]-FHPG. The labeled product was purified by HPLC on a reverse-phase C18 column, and eluted in 9 min with a mobile phase of 5% acetonitrile in water. The radiochemical yield was 7-17%, with an average of 10% in 10 runs (corrected for decay to EOB). The radiochemical purity was > 99%, and specific activities with an average of 526 mCi/mumol were obtained. The synthesis time was 70-80 min, including HPLC purification and determination of radiochemical purity and specific activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8940722     DOI: 10.1016/0969-8051(96)00075-3

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  14 in total

Review 1.  Imaging transgene expression with radionuclide imaging technologies.

Authors:  S S Gambhir; H R Herschman; S R Cherry; J R Barrio; N Satyamurthy; T Toyokuni; M E Phelps; S M Larson; J Balatoni; R Finn; M Sadelain; J Tjuvajev; R Blasberg
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Imaging gene expression: principles and assays.

Authors:  S S Gambhir; J R Barrio; H R Herschman; M E Phelps
Journal:  J Nucl Cardiol       Date:  1999 Mar-Apr       Impact factor: 5.952

Review 3.  Defining the success of cardiac gene therapy: how can nuclear imaging contribute?

Authors:  Norbert Avril; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-23       Impact factor: 9.236

Review 4.  Imaging for infection: from visualization of inflammation to visualization of microbes.

Authors:  Justin Ady; Yuman Fong
Journal:  Surg Infect (Larchmt)       Date:  2014-12       Impact factor: 2.150

5.  Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography.

Authors:  S S Gambhir; J R Barrio; M E Phelps; M Iyer; M Namavari; N Satyamurthy; L Wu; L A Green; E Bauer; D C MacLaren; K Nguyen; A J Berk; S R Cherry; H R Herschman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  [18F]FHPG positron emission tomography for detection of herpes simplex virus (HSV) in experimental HSV encephalitis.

Authors:  A R Buursma; E F J de Vries; J Garssen; D Kegler; A van Waarde; J Schirm; G A P Hospers; N H Mulder; W Vaalburg; H C Klein
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  5-[18F]Fluoroalkyl pyrimidine nucleosides: probes for positron emission tomography imaging of herpes simplex virus type 1 thymidine kinase gene expression.

Authors:  Ann-Marie Chacko; Eric Blankemeyer; Brian P Lieberman; Wenchao Qu; Hank F Kung
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

8.  Positron emission tomography (PET) imaging with (18)F-based radiotracers.

Authors:  Mian M Alauddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

9.  In vivo evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-beta-D-arabinofuranosyluracil ([18F]FIAU) and 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression.

Authors:  Mian M Alauddin; Antranic Shahinian; Ryan Park; Michel Tohme; John D Fissekis; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 10.057

10.  In Vivo Noninvasive Imaging for Gene Therapy.

Authors:  Georges Vassaux; Thomas Groot-Wassink
Journal:  J Biomed Biotechnol       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.